← Leaderboards
Jeffrey Paul Mackeigan
Michigan State University
$4,522,117
Attributed
$6,119,554
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $730.4K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,119,554 · 6
By mechanism
R01$4,925,155 · 3
R21$1,194,399 · 3
Top collaborators
- William S. Hlavacek5 shared
- Russell Jones1 shared
Most similar at Michigan State University
Same institution · by research overlap
- Sarah H. Elsea$3,970,721
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsCell LineResponseSignal TransductionCessation Of LifeTumor ProgressionTumorIn VivoNeoplastic CellMediatingPhysiologicalDesignComplexMolecularProteinsCell DeathApoptosisBaseKineticsTherapeutic TargetCancer PatientRna InterferenceCell SurvivalMutant
Grant awards (19)
ULK Inhibition Rewires Tumor and Immune Cell Metabolism$730,407
R01 · FY2025 · CA · contact PI
ULK1 Inhibitor in Combination with Immune Checkpoint Blockade in PancreaticCancer$173,764
R21 · FY2024 · CA · contact PI
ULK1 Inhibitor in Combination with Immune Checkpoint Blockade in PancreaticCancer$219,491
R21 · FY2023 · CA · contact PI
Therapeutic potential of targeting DNA repair deficiency in TSC$179,252
R21 · FY2022 · CA · contact PI
Evaluating a Novel Autophagy Inhibitor in KRAS-Driven Lung Cancer$402,401
R21 · FY2021 · CA · contact PI
Therapeutic potential of targeting DNA repair deficiency in TSC$219,491
R21 · FY2021 · CA · contact PI
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer$456,293
R01 · FY2019 · CA · contact PI
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer$470,406
R01 · FY2018 · CA · contact PI
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer$484,156
R01 · FY2017 · CA · contact PI
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer$515,556
R01 · FY2016 · CA · contact PI
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer$538,056
R01 · FY2015 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$252,656
R01 · FY2013 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$268,783
R01 · FY2012 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$126,801
R01 · FY2012 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$268,783
R01 · FY2011 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$127,300
R01 · FY2011 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$277,095
R01 · FY2010 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$131,768
R01 · FY2010 · CA · contact PI
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and Death$277,095
R01 · FY2009 · CA · contact PI